CD8A and Glanzmann thrombasthenia 1: Our analysis demonstrated that the percentages of CD3+ and CD4+ and the CD4+/CD8+ ratios were all significantly increased in GT patients treated with ADI, indicating that immune function of GT patients improved after ADI adjuvant therapy.